Brean Murray Maintains 'Buy' on Keryx (KERX); Focus Shifts to Less Risky Zerenex
Tweet Send to a Friend
Get Alerts KERX Hot Sheet
Price: $8.04 +0.50%
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade KERX Now!
Brean Murray Carret & Co. maintains a 'Buy' on Keryx Biopharmaceuticals (NASDAQ: KERX) price target halved to $5.
Analyst, Jonathan Aschoff, said, "KERX announced top-line data for the Phase 3 X-PECT trial, where perifosine in combo with capecitabine failed to meet the primary endpoint in the treatment of coloretal cancer (CRC). Due to this outcome, KERX is also reevaluating the Phase 3 program of perifosine in relapsed and refractory multiple myeloma patients. Given the unfortunate outcome in CRC, our focus is now on the Phase 3 program for Zerenex...We continue to believe that Zerenex offers a great deal of value to patients and to shareholders with the share price down where it is at present."
Aschoff lowers FY12 loss from (0.44) to (0.47) and FY13 from (0.14) to (0.37)
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $4.98 yesterday, with a 52 week range of $2.27-$5.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jonathan Aschoff, said, "KERX announced top-line data for the Phase 3 X-PECT trial, where perifosine in combo with capecitabine failed to meet the primary endpoint in the treatment of coloretal cancer (CRC). Due to this outcome, KERX is also reevaluating the Phase 3 program of perifosine in relapsed and refractory multiple myeloma patients. Given the unfortunate outcome in CRC, our focus is now on the Phase 3 program for Zerenex...We continue to believe that Zerenex offers a great deal of value to patients and to shareholders with the share price down where it is at present."
Aschoff lowers FY12 loss from (0.44) to (0.47) and FY13 from (0.14) to (0.37)
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $4.98 yesterday, with a 52 week range of $2.27-$5.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- SunPower (SPWR) Not Worth More than $13/Share, Says Goldman
- Wells Fargo Downgrades Aruba Networks (ARUN) to Market Perform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Brean Murray Carret & Co.
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
